Correvio Pharma’s (CORV) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Correvio Pharma (NASDAQ:CORV) in a report released on Thursday morning, AnalystRatings.com reports. They currently have a $7.00 target price on the stock.

Separately, ValuEngine upgraded shares of Correvio Pharma from a sell rating to a hold rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $7.00.

NASDAQ:CORV opened at $1.76 on Thursday. Correvio Pharma has a one year low of $1.43 and a one year high of $5.24. The company has a market cap of $84.85 million, a P/E ratio of -1.98 and a beta of 0.43. The firm’s fifty day moving average price is $1.89 and its two-hundred day moving average price is $2.66. The company has a debt-to-equity ratio of 7.21, a current ratio of 2.80 and a quick ratio of 2.42.



Correvio Pharma (NASDAQ:CORV) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.05). Correvio Pharma had a negative net margin of 107.91% and a negative return on equity of 427.34%. The company had revenue of $7.39 million during the quarter, compared to analyst estimates of $7.64 million. As a group, equities research analysts expect that Correvio Pharma will post -0.71 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Correvio Pharma in the fourth quarter valued at $39,000. Financial Counselors Inc. acquired a new position in shares of Correvio Pharma in the first quarter valued at about $116,000. LPL Financial LLC grew its stake in shares of Correvio Pharma by 177.1% in the second quarter. LPL Financial LLC now owns 63,855 shares of the company’s stock valued at $138,000 after acquiring an additional 40,815 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Correvio Pharma by 45.9% in the second quarter. Commonwealth Equity Services LLC now owns 105,623 shares of the company’s stock valued at $228,000 after acquiring an additional 33,250 shares in the last quarter. Finally, Columbia Pacific Advisors LLC grew its stake in shares of Correvio Pharma by 29.8% in the first quarter. Columbia Pacific Advisors LLC now owns 130,709 shares of the company’s stock valued at $413,000 after acquiring an additional 30,000 shares in the last quarter. Hedge funds and other institutional investors own 44.60% of the company’s stock.

About Correvio Pharma

Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.

Featured Article: What is quantitative easing?

Analyst Recommendations for Correvio Pharma (NASDAQ:CORV)

Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.